Novo Nordisk A/S (NOVO-B.CO)
| Previous Close | 903.30 |
| Open | 903.00 |
| Bid | 925.20 x 0 |
| Ask | 924.80 x 0 |
| Day's Range | 900.00 - 928.90 |
| 52 Week Range | 504.40 - 932.00 |
| Volume | |
| Avg. Volume | 2,730,580 |
| Market Cap | 4.124T |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 46.59 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 12.80 (1.42%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | N/A |
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
- GlobeNewswire
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the
- GlobeNewswire
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors. The trial achieved its co-primary endp
